Key result
AI-driven pharmacogenomic modelling yields favourable drug responses in 93% of cardiovascular patients.
Why the study?
AI-driven pharmacogenomic modelling for optimized drug response in cardiovascular diseases was assessed to evaluate its effectiveness and acceptability.
Observational (n=100)
In a cohort of 100 patients with cardiovascular disease, 93% were reported to have a favourable response to AI-driven pharmacogenomic modelling.
May support AI pharmacogenomic exploration in CVD; hypothesis-generating and requires randomized validation before practice change.
Background: This study was conducted to assess the AI- driven pharmacogenomic modelling for optimized drug response in cardiovascular diseases. Material and methods: In this study, overall 100 subjects with cardiovascular diseases were included. Studies were included if they focused on the topics of cardiovascular disease, personalised medicine, or artificial intelligence. There were no restrictions on study design, location, or gender. Studies were excluded if they did not focus on CVD, personalized medicine, or AI. Additionally, duplicate records, non-English language publications, non-peer-reviewed works, studies utilizing non-standard AI techniques, and studies with low-quality design were excluded. The response to AI was assessed among the subjects. Statistical analysis was conducted using SPSS software. Results: In this study, there were 56 males and 44 females. Out of 100, 93 subjects showed favourable response to AI while the remaining 7 subjects showed unfavourable response. Conclusion: From the results of this study can be concluded that AI driven pharmacogenomic modelling for optimized drug response in cardiovascular diseases is an acceptable approach.
No takes yet. Share an insight, caveat, or question.
Rachana Emmanuel Mhetre, Mrithika S, Mohamed Nizam Al Deen Shah, Ranjitha Naveen Hegde, Kalyani G, Dipasha K Rao (2025) conducted an observational in Cardiovascular diseases (n=100). AI-driven pharmacogenomic modelling was evaluated on Favourable response to AI software. Among 100 subjects with cardiovascular diseases, 93% demonstrated a favourable response to AI-driven pharmacogenomic modelling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: